AzTrials
AzTrials

Mucogingival DefectsNCT06701799

Clinical Evaluation of Gingival Biotype Changes Using a Coronally Advanced Flap (CAF) in Combination with Leucocyte and Platelet- Rich Fibrin (L-PRF) Membranes of Different Thickness for the Treatment of RT1 Gingival Recession: a Randomized Controlled Clinical Trial.

A study testing CAF+ L-PRF 1 mm and CAF+ L-PRF 2 mm in people with Mucogingival Defects and Recession, Gingival, run by G. d'Annunzio University at 1 site in Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Gingival thickness plays a key role not only in the etiology but also in the treatment of gingival recessions. More recently, authors reported that as the gingival thickness decreases, the gingival recession severity increases . Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
What is being tested?
CAF+ L-PRF 1 mm and CAF+ L-PRF 2 mm
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteItaly
Study dates
30 Nov 2024to 30 Nov 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Systemic factors (no systemic diseases; no coagulation disorders; no medications affecting periodontal status in the previous 6 months; no pregnancy or lactation)
  • Never smokers/former smokers >=10years
  • Full-mouth plaque score (FMPS)and a full-mouth bleeding score (FMBS) lower than 15%
  • No periodontal surgery on the experimental sites
  • >= 20 teeth without mobility
  • No presence of cervical carious lesions or periapical lesions at experimental sites
  • At least one RT1 buccal gingival recession

Who cannot join

  • Systemic diseases
  • Coagulation disorders
  • Medications affecting periodontal status in the previous 6 months
  • Pregnancy or lactation
  • Smokers

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Michele Paolantonio, MD, DDS contact

3395204073

michelepaolantonio@gmail.com

Italy1 site
  • Department of Innovative Technologies in Medicine and Dentistry, Chieti

    Chieti, CH, 66100

    Michele Paolantonio, MD, DDS, 3395204073, michelepaolantonio@gmail.com

    Michele Paolantonio, MD, DDS

Other trials in Italy

About this study

Official title: CAF in Association with Different Thickness of L-PRF Membranes of for the Treatment of RT1 Gingival Recession: a Randomized Controlled Clinical Trial.

Gingival thickness plays a key role not only in the etiology but also in the treatment of gingival recessions. More recently, authors reported that as the gingival thickness decreases, the gingival recession severity increases . When gingival inflammation occurs, if the tissue is thin the consequent destruction can quickly produce a gingival recession (GR) .

When treating a gingival recession, the clinician should aim not only to completely cover the exposed root surface but also to prevent a future recession recurrence. The treatment gold standard is the CAF associated with connective tissue graft. This technique has demonstrated high rates in gingival recession reduction and positive predictability in obtaining complete root coverage. However, some disadvantages about this surgical approach can be easily highlighted: patients experience more discomfort, longer chair-time it's necessary and a second wound area is created. In this scenario, The Platelet rich in fibrin and leucocyte (L-PRF) could be a valuable alternative treatment of gingival defects. It's a platelet concentrate, obtained by a fast and simple procedure that does not require anticoagulant and bovine thrombin. It can also be categorized as a live tissue thanks to platelets, leukocytes, growth factors and stem cells trapped in a polymerized fibrin mesh. L- PRF is used in various fields of regenerative medicine; It promotes stabilization and revascularization of the flaps, contributes to soft tissue wound healing and reduces post-operative discomfort. The purpose of this study will be to evaluate if the different thickness of platelet- rich fibrin (L-PRF) membranes in association with a Coronally Advanced Flap (CAF), for the treatment of RT1 gingival recessions, may influence the Complete Root Coverage (CRC).

Read the detailed description

This prospective, randomized and controlled clinical trial will compare: CAF +1 mm thick L-PRF membrane versus CAF +2 mm thick L-PRF membrane for the treatment of RT1 gingival recession. From each patient a single recession on a single tooth will be selected. Clinical parameters will be evaluated at base-line and after 6 months.

The protocol is approved by the "G. D'Annunzio" University Ethical Committee. This study is in accordance with the Declaration of Helsinki of 1975. Patients will be recruited from the Unit of Periodontology, "G. D'Annunzio" University of Chieti-Pescara, Italy. All the volunteer candidates will sign a written informed consent.

The trial director will be responsible for randomly assigning patients to treatment after enrollment and will not involve with the clinical interventions or the study measurements. A computer-generated table will be used to make the random assignment, known only to the trial director. An opaque envelope will conceal group allocation and will be opened just before the intervention surgery. Matching between group and treatment will be performed by a figure extraneous to the experimentation, responsible even for keeping and breaking the blinding, and known only to him.

Patients and examiners will be masked to group membership; clinical examiners will be blinded to each other. The study analyst will be also blind to group membership. The analyst will receive the data by groups labeled as A and B. The blind will not be broken until after study completion. Complete root coverage (CRC) will be assumed as the main outcome at 6 months after treatment. At baseline and 6 months after surgery, the following clinical measurements will be also recorded on the mid-buccal point of exposed root surface: Gingival thickness (GT) will be determined using a stent at a mid-buccal location about 1 mm apical to the pocket depth (PD) level with a #15 endodontic reamer with a silicon disk stop. The soft tissue will be gently pierced at a 90° angle, until hard tissue will be felt. Once the silicon disk will be in contact with the soft tissue surface, it will be fixed by a drop of cyanoacrylate adhesive. After the careful removal of the reamer, the distance between the reamer tip and the stop will be measured with a calliper accurate to the nearest 0.1 mm. The other measurements will be taken with a periodontal probe and will be recorded to the nearest millimetre as follows: Gingival recession (GR) will be measured as the distance from the cement-enamel junction (CEJ) to the mid-buccal point of the gingival margin. PD and Clinical attachment level (CAL) will be measured as the distance between the bottom of the pocket and the gingival margin and CEJ, respectively. Keratinized tissue (KT) will be recorded from the mid-buccal point of the gingival margin to the mucogingival junction. Root coverage esthetic score (RES) (Cairo et al., 2009) will be used for assessing aesthetic outcomes of root coverage procedures. PROMs will also be evaluated. The degree of general discomfort (D) experienced will be assessed on a VAS scale (0-10). Patient-reported aesthetic satisfaction (PRES) at T1 will also be quantified on a VAS scale (0-10). Overall treatment satisfaction (OTS) at T1 will be assessed by asking each patient if they would undergo surgery again (yes/no). Thirty ml of blood samples will be collected in 10-ml tubes without anticoagulant and promptly centrifuged at 3,000 revolutions per minute for 10 minutes. The L-PRF membranes will be realized by a standardized compression of the clot for 120 seconds with 130 grams; the membranes will be put one on each other till obtaining a resultant membrane of the desired thickness: 1 or 2 mm. Exposed and intrasulcular root surface will be accurately scaled using curettes. A coronally advanced flap technique (CAF) will be used to treat the recession defect. The flap will be elevated as follows: an intrasulcular incision will be performed around the selected tooth, the incision moves on contiguous papillae area, avoiding the gingival margin of adjacent teeth. From each side, from coronal to apical, an oblique incision will be carried out. A split-full-split dissection will be undertaken until the CEJ could be passively cover by the flap. Both papillae will be de-epithelialized. The 1 mm L-PRF membrane will be be placed over the exposed root surface of the CAF+ L-PRF 1mm group and the 2 mm L-PRF membrane in the CAF+ L-PRF 2 mm group. The gingival defect will be fully lined by grafts that mildly cover the neighbouring sub-papillae areas. In each group, flap will be coronally positioned and sutured over the enamel in a tension-free position.

All patients will receive 2 g/day amoxicillin+clavulanic acid for 6 days for post-operative infection prevention; 400 mg of oral ibuprofen, twice daily, will control the pain; 0.12% chlorhexidine rinses, twice daily for 3 weeks, will be prescribe to the patients. Sutures will be removed after 14 days. Only 2-4 weeks after sutures removal, respectively, cautious brushing by a soft toothbrush and interdental brushing will be recommend; meantime, the patients use a 1% chlorhexidine gel twice daily. Weekly supra-gingival professional hygiene and motivational reinforcement will be administer to the patients for 6 weeks.

Being tested
CAF+ L-PRF 1 mm, CAF+ L-PRF 2 mm
Keywords
Coronally Advanced Flap, L-PRF, Platelet concentrate, Gingival Recession, Gingival Biotype
Medical subject headings
Gingival Recession

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CAF+ L-PRF 1 mmProcedure or surgery

    The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.

  • CAF+ L-PRF 2 mmProcedure or surgery

    The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.

Study groups in NCT06701799
Study groupRoleWhat they receive
CAF+ L-PRF 2 mmExperimentalCoronally Advanced Flap combined with in combination with a membrane 2 mm in thickness of L-PRF for the Treatment of RT1 Gingival Recession.
Receives: Procedure: CAF+ L-PRF 2 mm
CAF+ L-PRF 1 mmExperimentalCoronally Advanced Flap combined with in combination with a membrane 1 mm in thickness of L-PRF for the Treatment of RT1 Gingival Recession.
Receives: Procedure: CAF+ L-PRF 1 mm

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Complete root coverage

    Percentage of experimental sites that achieved complete root surface coverage.

    Measured: 6 months

Secondary outcomes (8)
  1. Keratinized tissue width

    Distance between gingival margin and Mucogingival Junction.

    Measured: 6 months

  2. Clinical attachment level

    Distance between cementoenamel junction(CEJ) and depth of the pocket.

    Measured: 6 months

  3. Gingival Recession

    Distance from cementoenamel junction and gingival margin.

    Measured: 6 months

  4. Gingival thickness

    Gingival tissue thickness evaluated 2 mm apical to the recession.

    Measured: 6 months

  5. Pocket depth

    Distance between gingival margin and bottom of the pocket.

    Measured: 6 months

  6. Discomfort

    Evaluation of post-operative discomfort using Visual Analogue Scale (VAS).The scale is represented by a straight horizontal line of fixed length, generally 10 cm. Extremities are defined as extreme limits of the parameter to be measured, oriented from left (worst) to right (best).

    Measured: 4 weeks

  7. Patient-Reported Esthetic Satisfaction

    Patient-reported esthetic satisfaction (PRES) quantified on a VAS scale (0-10), will be recorded after observing simultaneously 2 standardized photographs showing the treated site +2 mesial and 2 distal teeth and the MGJ.

    Measured: 6 months

  8. Root Coverage Esthetic Score

    This score evaluates five variables: level of the gingival margin, marginal tissue contour, soft tissue texture, mucogingival junction alignment, and gingival color.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2024
  2. Study start30 Nov 2024 (estimated)
  3. Primary completion31 May 2025 (estimated)
  4. Study completion30 Nov 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized Controlled Clinical Trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06701799
Sponsor's protocol ID
211124
Status last verified
Nov 2024
First submitted
19 Nov 2024
Last updated
22 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing CAF+ L-PRF 1 mm and CAF+ L-PRF 2 mm in people with Mucogingival Defects and Recession, Gingival, run by G. d'Annunzio University at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 22 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Michele Paolantonio, MD, DDS (3395204073, michelepaolantonio@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Complete root coverage (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in